systemat
review
avail
evid
embas
medlin
cochran
librari
diagnost
accuraci
clinic
impact
commerci
avail
rapid
result
hour
molecular
diagnost
respiratori
virus
compar
convent
molecular
test
qualiti
includ
studi
assess
use
qualiti
assess
diagnost
accuraci
studi
criteria
diagnost
test
accuraci
dta
studi
cochran
risk
bia
assess
risk
bia
nonrandom
studi
intervent
criteria
random
observ
impact
studi
respect
sixtythre
dta
report
studi
metaanalyz
pool
sensit
confid
interv
ci
specif
ci
detect
either
influenza
viru
n
respiratori
syncyti
viru
rsv
n
influenza
viru
rsv
n
viral
panel
includ
influenza
viru
rsv
n
includ
impact
studi
random
heterogen
result
therefor
inconclus
howev
suggest
implement
rapid
diagnost
hospit
care
set
consid
acut
respiratori
tract
infect
rti
high
diseas
burden
third
caus
death
worldwid
respiratori
virus
predomin
caus
pathogen
patient
hospit
acut
rti
account
microbiolog
etiolog
rapid
identif
viral
etiolog
may
improv
effect
patient
manag
influenc
decis
make
antibiot
treatment
antivir
therapi
hospit
admiss
length
stay
implement
infectioncontrol
measur
prevent
transmiss
may
also
lead
avoid
unnecessari
cost
antimicrobi
resist
reduc
unnecessari
prescript
antibiot
decad
ago
transit
convent
techniqu
viral
cultur
immunoassay
reversetranscript
polymeras
chain
reaction
rtpcr
techniqu
result
reduct
overal
antibiot
use
hospit
patient
lower
rti
although
faster
comparison
convent
techniqu
rtpcrbase
diagnost
still
took
hour
sampl
result
wherea
nowaday
access
rapid
diagnost
turnaround
time
hour
whether
rapid
method
lead
improv
patient
outcom
howev
still
debat
first
wide
rang
rapid
test
avail
larg
differ
diagnost
accuraci
review
evalu
accuraci
avail
rapid
test
respiratori
virus
either
includ
heterogen
group
test
includ
ultrarapid
less
sensit
antigenbas
test
sensit
slightli
slower
molecular
test
compar
rapid
test
outdat
techniqu
viral
cultur
immunoassay
focus
viral
pathogen
mostli
influenza
viru
focus
specif
assay
guid
physician
hospit
choic
rapid
diagnost
tool
valu
interpret
result
diagnost
test
accuraci
dta
review
avail
molecular
rapid
test
compar
best
avail
refer
standardrtpcr
molecular
methodsi
essenti
second
even
test
demonstr
high
accuraci
conflict
conclus
whether
implement
test
result
better
patient
outcom
review
clinic
impact
rapid
molecular
test
summar
assess
sourc
heterogen
explain
discrep
result
therefor
highli
need
review
provid
overview
avail
molecular
rapid
test
provid
result
detect
respiratori
virus
within
hour
systemat
summar
qualiti
metaanalyz
result
dta
studi
systemat
review
studi
evalu
clinic
impact
rapid
molecular
test
respiratori
virus
method
follow
guidanc
provid
cochran
dta
work
group
systemat
review
regist
prospero
databas
systemat
literatur
search
dta
clinic
impact
studi
conduct
supplementari
materi
search
perform
medlin
embas
cochran
librari
august
inclus
exclus
criteria
screen
process
describ
supplementari
materi
respect
data
extract
dta
clinic
impact
studi
conduct
systemat
manner
supplementari
materi
methodolog
qualiti
includ
studi
review
use
qualiti
assess
diagnost
accuraci
studi
criteria
dta
studi
cochran
risk
bia
tool
random
clinic
impact
studi
risk
bia
nonrandom
studi
intervent
robinsi
tool
nonrandom
clinic
impact
studi
sensit
specif
calcul
use
conting
tabl
index
test
includ
dta
studi
sensit
specif
individu
studi
correspond
confid
interv
ci
present
pair
forest
plot
use
bivari
randomeffect
model
metaanalyz
logittransform
sensit
specif
obtain
summari
estim
togeth
randomeffect
confid
predict
interv
model
take
account
precis
sensit
specif
estim
studi
use
binomi
distribut
ie
weight
averag
incorpor
addit
variabl
beyond
chanc
exist
studi
ie
randomeffect
model
result
plot
receiv
oper
characterist
roc
space
confid
predict
interv
confid
region
reflect
precis
pool
point
estim
wherea
predict
region
repres
region
individu
result
new
larg
studi
evalu
diagnost
accuraci
rapid
assay
expect
plot
sensit
specif
estim
frequent
describ
assay
pool
per
assay
heterogen
studi
assess
subgroup
analys
use
bivari
randomeffect
regress
differ
studi
popul
differ
assay
differ
virus
assess
differ
studi
design
studi
differ
qualiti
clinic
impact
studi
descript
summari
qualiti
includ
studi
given
result
clinic
impact
studi
pool
quantit
present
per
clinic
outcom
arrang
studi
qualiti
analys
perform
r
studio
roc
plot
made
use
stata
version
softwar
screen
figur
separ
report
includ
metaanalysi
individu
dta
studi
public
supplementari
materi
main
characterist
includ
dta
report
describ
qualiti
includ
dta
studi
n
assess
use
criteria
summar
supplementari
figur
biggest
concern
term
qualiti
minor
includ
studi
gave
clear
descript
select
criteria
andor
use
cohort
design
inclus
patient
specimen
term
flow
studi
use
sampl
frozen
index
refer
test
use
multipl
differ
molecular
refer
standard
andor
exclud
sampl
invalid
result
either
index
test
refer
standard
index
test
major
studi
unclear
whether
result
interpret
without
knowledg
result
refer
test
overal
pool
sensit
rapid
molecular
test
ci
pool
specif
ci
forest
plot
sensit
specif
includ
studi
shown
figur
roc
plot
sensit
specif
frequent
assess
assay
depict
figur
subgroup
analys
conduct
investig
heterogen
sensit
specif
tabl
sensit
differ
index
test
rang
ci
aler
influenza
b
assay
ci
simplexa
flu
ab
rsv
kit
p
specif
assay
detect
panel
virus
eg
filmarray
advansur
eplex
rp
panel
significantli
lower
specif
assay
detect
influenza
viru
andor
rsv
p
subgroup
analys
base
differ
studi
design
show
increas
sensit
cohort
studi
compar
casecontrol
studi
p
pool
sensit
studi
includ
children
n
ci
compar
pool
sensit
ci
adult
n
p
wherea
pool
specif
one
studi
salez
neg
test
sampl
includ
specif
could
calcul
studi
therefor
exclud
pool
analysi
specif
studi
outstandingli
low
specif
due
casecontrol
design
inclus
low
number
virusneg
patient
screen
figur
includ
clinic
impact
studi
characterist
includ
clinic
impact
studi
describ
tabl
implement
diagnost
rapid
molecular
test
combin
procalcitonin
measur
studi
two
studi
implement
guidelin
treatment
decis
base
rapid
test
result
wherea
studi
chang
treatment
recommend
antibiot
stewardship
made
treatment
consequ
rapid
test
describ
five
studi
random
diagnost
impact
trial
studi
use
nonrandom
beforeaft
design
studi
observ
noncompar
studi
studi
includ
patient
center
three
studi
place
rapid
test
point
care
wherea
other
locat
diagnost
test
microbiolog
laboratori
seven
studi
sponsor
manufactur
diagnost
test
median
number
includ
patient
studi
iqr
studi
n
includ
adult
patient
filmarray
use
frequent
studi
diagnost
intervent
test
qualiti
assess
studi
summar
supplementari
figur
nonrandom
studi
suffer
potenti
confound
bia
bia
outcom
measur
result
impact
studi
heterogen
clinic
outcom
studi
categor
summar
tabl
studi
higher
qualiti
top
turnaround
time
rapid
molecular
test
vs
refer
molecular
techniqu
significantli
faster
studi
assess
turnaround
time
n
implement
rapid
molecular
test
decreas
number
antibiot
prescript
durat
antibiot
treatment
multivari
adjust
beforeaft
studi
report
significantli
lower
percentag
antibiot
prescript
patient
test
simplexa
flu
ab
rsv
kit
second
season
compar
patient
test
laboratorydevelop
rtpcr
first
season
one
beforeaft
studi
report
signific
reduct
durat
antibiot
treatment
studi
adjust
differ
proport
influenza
virusposit
patient
significantli
higher
second
intervent
season
oseltamivir
prescript
appropri
influenza
virusposit
patient
accord
random
studi
nonrandom
studi
two
nonrandom
compar
studi
show
effect
rapid
test
oseltamivir
prescript
number
hospit
admiss
reduc
rapid
molecular
test
studi
among
random
studi
show
decreas
length
hospit
stay
among
admit
patient
length
hospit
stay
reduc
studi
among
random
studi
howev
smaller
potenti
underpow
compar
random
studi
show
signific
effect
safeti
outcom
mortal
seriou
advers
event
intens
care
unit
admiss
andor
readmiss
differ
intervent
control
group
term
effici
studi
report
lower
cost
therapi
use
rapid
molecular
test
studi
report
reduct
number
chest
radiograph
influenza
virusposit
patient
effect
use
isol
facil
studi
unadjust
beforeaft
studi
report
signific
reduct
mean
droplet
isol
day
reduct
isol
day
suspect
influenza
vs
day
p
increas
isol
day
confirm
influenza
viru
infect
vs
day
p
metaanalysi
dta
studi
molecular
rapid
test
respiratori
virus
show
test
accur
pool
sensit
ci
pool
specif
ci
subgroup
analysi
coba
liat
influenza
ab
system
reliabl
detect
influenza
viru
sensit
simplexa
flu
ab
rsv
kit
reliabl
detect
influenza
viru
rsv
sensit
filmarray
simultan
test
panel
virus
sensit
overal
molecular
test
better
sensit
children
adult
presum
due
higher
viral
load
children
studi
clinic
impact
rapid
molecular
test
larg
variat
design
qualiti
nevertheless
unanim
found
significantli
decreas
turnaround
time
addit
reduc
length
hospit
stay
increas
appropri
use
oseltamivir
influenza
virusposit
patient
potenti
reduct
cost
addit
radiograph
compar
convent
molecular
method
observ
major
highqual
studi
effect
seen
antibiot
prescript
durat
antibiot
therapi
use
inhospit
isol
measur
number
hospit
admiss
first
systemat
review
compar
pool
diagnost
accuraci
multipl
rapid
molecular
assay
analyz
clinic
outcom
systemat
review
topic
either
includ
nonrapid
molecular
assay
focus
particular
assay
also
includ
nonmolecular
rapid
test
lower
sensit
compar
molecular
assay
studi
shown
superior
accuraci
molecular
assay
compar
rapid
antigen
test
pool
result
assay
use
differ
underli
techniqu
give
pessimist
estim
diagnost
accuraci
molecular
test
potenti
practic
concern
molecular
test
compar
antigen
test
increas
cost
longer
turnaround
time
complic
procedur
larg
overcom
recent
technolog
innov
molecular
test
replac
antigenbas
rapid
assay
therefor
comparison
use
molecular
assay
gold
standard
review
includ
pathogenspecif
singleplex
multiplex
assay
detect
rang
respiratori
virus
wherea
review
studi
special
focu
assay
detect
pathogen
mainli
influenza
viru
sometim
rsv
viral
pathogen
influenza
viru
rsv
also
high
burden
diseas
detect
may
clinic
consequ
antivir
treatment
applic
isol
measur
hospit
set
depend
clinic
set
patient
popul
assay
capabl
detect
panel
virus
may
therefor
increas
interest
rapid
test
replac
convent
molecular
test
determin
rapid
test
implement
overal
diagnost
accuraci
multiplex
test
may
import
individu
pathogen
accuraci
wherea
current
diagnost
accuraci
review
overal
sensit
specif
often
given
per
viru
instead
per
assay
howev
note
judg
discrep
viral
result
similarli
multiplex
singleplex
assay
result
poorer
diagnost
accuraci
mainli
specif
multiplex
assay
therefor
compar
differ
avail
rapid
molecular
assaysfor
exampl
simplexa
flu
ab
rsv
filmarrayit
alway
note
differ
diagnost
accuraci
assay
result
test
differ
number
viral
pathogen
diagnost
accuraci
per
individu
viral
pathogen
may
similar
former
studi
assess
effect
test
convent
multiplex
assay
provid
result
within
hour
show
effect
antibiot
treatment
hospit
length
stay
howev
rapid
test
respiratori
virus
analysi
antibiot
prescript
perform
patient
due
miss
data
antibiot
prescript
patient
control
arm
ten
intervent
arm
c
multivari
analysi
adjust
confound
age
locat
sampl
collect
receipt
influenza
vaccin
immunosuppress
statu
pregnanc
subgroup
analysi
viru
posit
patient
studi
gelfer
among
viru
posit
patient
patient
receiv
antimicrobi
includ
studi
kesk
viru
posit
patient
includ
inpati
durat
antibiot
therapi
patient
inappropri
antibiot
use
includ
e
subgroup
analysi
influenza
posit
patient
studi
busson
among
influenza
posit
patient
patient
test
rapid
molecular
test
work
hour
still
ed
test
result
includ
studi
rappo
among
influenza
posit
patient
patient
receiv
chest
radiograph
includ
multivari
analysi
number
chest
radiograph
f
quasi
random
random
process
rapid
viral
molecular
test
oneweek
refer
laboratori
pcr
test
follow
week
multivari
analysi
adjust
confound
age
immunosuppress
statu
asthma
admiss
icu
j
analysi
isol
facil
use
avail
patient
includ
second
season
inclus
k
studi
andrew
patient
admit
acut
medic
unit
medic
assess
centr
inclus
studi
turnaround
time
calcul
time
admiss
result
therefor
also
cover
time
admiss
swab
actual
taken
time
assess
elig
inclus
inform
consent
procedur
perform
l
studi
roger
patient
includ
emerg
depart
also
admiss
lead
longer
time
result
might
improv
impact
clinic
outcom
result
avail
initi
treatment
manag
establish
treat
physician
knowledg
first
review
specif
assess
clinic
impact
rapid
molecular
test
rapid
antigen
test
without
restrict
detect
influenza
viru
rsv
includ
studi
even
highqual
random
studi
show
heterogen
result
locat
rapid
test
point
care
studi
may
affect
turnaround
time
therebi
clinic
outcom
apart
differ
design
analysi
power
differ
implement
strategi
might
partial
explain
discrep
first
educ
train
personnel
physician
implement
rapid
test
diagnost
accuraci
potenti
effect
clinic
outcom
may
contribut
effect
clinic
outcom
second
combin
rapid
test
resultbas
guidelin
subsequ
clinic
manag
option
might
impact
standalon
diagnost
test
even
though
studi
describ
implement
diagnost
bundl
show
signific
effect
implement
might
partial
explain
limit
adher
guidelin
complic
factor
therein
identif
viral
pathogen
respiratori
tract
sampl
may
necessarili
attribut
causat
third
combin
rapid
test
anoth
diagnost
procalcitonin
biomarkerbas
assay
may
increas
persuas
rapid
viral
test
whether
bacteri
viral
caus
pathogen
howev
current
evid
effect
combin
respiratori
viral
test
procalcitonin
clinic
outcom
disappoint
strength
systemat
review
metaanalysi
dta
studi
follow
standard
protocol
inclus
studi
qualiti
assess
data
extract
statist
analysi
complet
possibl
exclud
studi
less
optim
studi
design
eg
casecontrol
studi
evalu
heterogen
use
subgroup
analys
furthermor
assess
clinic
impact
rapid
molecular
test
respiratori
virus
sinc
quantit
pool
clinic
impact
result
feasibl
due
heterogen
studi
design
qualiti
made
overal
conclus
clinic
endpoint
assess
least
studi
base
major
vote
studi
highest
qualiti
power
also
overview
avail
clinic
impact
studi
may
import
implic
design
futur
clinic
impact
studi
review
also
limit
first
due
poor
report
dta
studi
miss
inform
subgroup
analys
second
substanti
residu
heterogen
dta
studi
could
explain
subgroup
analys
residu
heterogen
therebi
differ
diagnost
accuraci
might
caus
differ
sampl
type
durat
clinic
symptom
associ
viral
load
includ
patient
exampl
factor
poorli
report
furthermor
assay
level
comparison
diagnost
accuraci
multiplex
assay
disadvantag
virus
assay
test
bigger
chanc
discrep
result
refer
test
therefor
mention
interpret
result
headtohead
comparison
accuraci
differ
assay
number
test
pathogen
also
taken
account
result
interpret
care
conclus
rapid
molecular
test
viral
pathogen
detect
provid
accur
result
even
though
result
clinic
impact
rapid
diagnost
test
conflict
highqual
evid
rapid
test
might
decreas
length
hospit
stay
might
increas
appropri
use
oseltamivir
influenza
virusposit
patient
without
lead
advers
result
therefor
suggest
consid
implement
rapid
molecular
test
within
hospit
set
recommend
perform
highqual
random
studi
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
